Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Progress in achieving long-term HIV remission

Pino, Mariaa; Paiardini, Mirkoa,b; Marconi, Vincent C.a,b,c,d

doi: 10.1097/COH.0000000000000487
PROGRESS IN ACHIEVING LONG-TERM HIV REMISSION: Edited by Jean-Daniel Lelièvre and Timothy J. Henrich

Purpose of review The purpose of the present review is to describe the major barriers to HIV eradication and assess the most promising cure strategies under investigation.

Recent findings There are significant challenges to achieve HIV eradication. These include the establishment of persistent latently infected cells, systemic chronic immune activation, and immune dysfunction. Since the announcement of the first HIV cure involving the Berlin patient, several attempts to reproduce these results have failed. Thus, it is widely accepted that long-term HIV remission would be a more feasible approach. Optimization of ART, immune-based therapies, therapeutic vaccinations, and gene editing, amongst others, are strategies aimed at controlling HIV in the absence of ART. These new strategies alone or in combination are being developed in preclinical studies and clinical trials and will provide further insight into whether long-term HIV remission is possible.

Summary The present review discusses several mechanisms that mediate the persistence of the HIV reservoir, clinical cases that provide hope in finding a functional cure of HIV, and promising interventional strategies being tested in preclinical studies and clinical trials that attempt to reduce the HIV reservoirs and/or boost the immune responses to control HIV in the absence of ART.

aYerkes National Primate Research Center (YNPRC), Emory Vaccine Center (EVC), Emory University

bEmory University School of Medicine

cEmory University Rollins School of Public Health

dAtlanta VA Medical Center, Atlanta, Georgia, USA

Correspondence to Vincent C. Marconi, VA Medical Center (111-RIM), Room 11C-138D, 1670 Clairmont Road, Decatur, GA 30033, USA. Tel: +1 404 616 0673; e-mail:

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.